Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Aphton presents phase III results for G17DT to foreign regulatory authority

March 7, 2003

Aldara shows benefit in pivotal studies in actinic keratosis and basal cell carcinoma

March 5, 2003

Preliminary results from CpG-7909 proof-of-principle study announced

March 4, 2003

HuMax-CD20 kills rituximab-resistant tumor cells in preclinical studies

Feb. 20, 2003

Phase II interim results for GI7DT plus chemotherapy in gastric cancer

Feb. 13, 2003

Increased survival associated with antitumor T-cell response in ovarian cancer

Feb. 10, 2003

Schering AG acquires Japanese and Asian rights to Campath

Feb. 7, 2003

Revimid granted fast track designation for relapsed or refractory multiple myeloma

Feb. 6, 2003

ALVAC-CEA/B7.1 under investigation in two colorectal cancer trials

Feb. 4, 2003

Recent developments at Seattle Genetics

Feb. 4, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...